Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
THE HOST PATHOGEN MAP INITIATIVE:
A NATIONAL RESEARCH CENTER FOR SYSTEMS BIOLOGY OF INFECTIOUS
DISEASE
OVERALL SUMMARY
Antibiotic-resistant pathogens are no longer an “emerging” threat as we face the reality of a return to the
pre-antibiotic age where treatments for the simplest microbial infections are ineffective. The Centers for
Disease Control and Prevention (CDC) estimates that more than 2 million people acquire a serious resistant
bacterial infection each year, and at least 23,000 deaths result. These numbers will increase dramatically as
our ability to fight these infections diminishes. Unfortunately, there have been no novel classes of antibiotics
discovered since the 1960s, underscoring the fact that novel approaches are required to develop novel
therapies to treat infection. As a result of these facts, it is now being realized that efforts to develop
host-directed therapies to treat infectious diseases may have unique advantages. Also, recent work has
revealed that although similar proteins may not be targeted by different pathogens, the same functional
pathways are often hijacked and re-wired during the course of infection. For these reasons, the study of
infectious disease is becoming increasingly dependent on knowledge of biological networks of multiple types,
including physical interactions among proteins and synthetic-lethal and epistatic interactions among genes,
which allow for deconstruction of functional pathways.
Here we seek support for a new effort, termed The Host Pathogen Map Initiative (HPMI)
(http://www.hpmi.ucsf.edu), aimed at comprehensively detailing the complex interactions among pathogenic
genes and proteins with the host factors they hijack and rewire during the course of infection. The HPMI is a
multi-campus initiative of the University of California, centered at UC San Francisco and UC-Berkeley, which
leverages advanced network mapping, computational analysis and infectious disease research platforms
developed by multiple HPMI investigators over the past decade. Thus primed, these platforms will be turned to
efficiently generate, assemble, and analyze host-pathogen molecular networks with a view towards using this
information in a clinical setting.
Over the next five years, the HPMI will seek to catalyze major phase transitions in pathogenesis research by
(1) Comprehensively mapping the networks of physical interactions using sets of secreted proteins from three
bacteria; Mycobacterium tuberculosis (Mtb), Staphylococcus aureus (SA) and Chlamydia trachomatis (CT) with
their host, revealing the protein complexes and higher-order molecular units targeted by these pathogens; (2)
Mapping the parallel networks of synthetic-lethal and epistatic interactions among the genes being targeted by
the bacteria, revealing the functional logic of pathogenesis; (3) Establishing the robust computational
methodology, end-user software, and databases for assembly and use of host-pathogen network maps in both
basic and clinical modalities; (4) Building a critical mass of leading infectious disease investigators worldwide
to expand HPMI into a global coordinated partnership; and (5) Training the current and next-generation of
scientists in Network Biology and its applications to infectious disease research.
Public Health Relevance Statement
OVERALL NARRATIVE
Although much attention has been devoted to developing therapeutic approaches that specifically target
pathogenic organisms, work must also be done to uncover host-directed therapies. To accomplish this, it is
critical to understand the many interactions between the pathogenic genes and proteins hijack and re-wire the
host machinery during infection. The Host Pathogen Map Initiative will apply systematic approaches to
comprehensively map the molecular networks that underlie pathogenesis and will use these maps as a key
resource for novel therapies.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AgeAntibioticsArtsAttentionBacteriaBacterial InfectionsBindingBiologicalBiological ProcessBiologyCaliforniaCell LineCellsCenters for Disease Control and Prevention (U.S.)Cessation of lifeChlamydia trachomatisClinicalCommunicable DiseasesComplexComputer AnalysisComputer softwareComputing MethodologiesDatabasesFaceFutureGene ProteinsGenesGoalsInfectionInfectious Diseases ResearchIntegration Host FactorsKnowledgeLaboratoriesLogicMapsMissionModalityModelingMolecularMycobacterium tuberculosisOrganismPathogenesisPathogenicityPathway interactionsPatientsPhase TransitionPrincipal InvestigatorProteinsResearchResearch PersonnelResourcesSamplingSan FranciscoScienceScientistStaphylococcus aureusSystemSystems BiologyTechnologyTherapeuticTherapeutic InterventionTrainingUniversitiesWorkbacterial resistancedrug resistant pathogenfightingmicrobialmolecular modelingnext generationnovelnovel strategiesnovel therapeuticspathogenprotein complex
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
17-August-2018
Project End Date
31-July-2022
Budget Start Date
01-August-2020
Budget End Date
31-July-2021
Project Funding Information for 2020
Total Funding
$2,000,000
Direct Costs
$1,989,183
Indirect Costs
$376,565
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Allergy and Infectious Diseases
$2,000,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U19AI135990-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U19AI135990-03
Patents
No Patents information available for 5U19AI135990-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U19AI135990-03
Clinical Studies
No Clinical Studies information available for 5U19AI135990-03
News and More
Related News Releases
No news release information available for 5U19AI135990-03
History
No Historical information available for 5U19AI135990-03
Similar Projects
No Similar Projects information available for 5U19AI135990-03